GC Genome Corporation (KOSDAQ:340450)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,900.00
-100.00 (-1.43%)
Sep 18, 2026, 3:30 PM KST

GC Genome Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
5,4154,044-1,257-550.1-3,763293.2
Depreciation & Amortization
2,6542,8673,2193,5412,8072,057
Loss (Gain) From Sale of Assets
223.96139.05-1.37-1.5744.8913.83
Asset Writedown & Restructuring Costs
--1,125---
Loss (Gain) From Sale of Investments
-1,828-1,828----
Loss (Gain) on Equity Investments
-553.47-553.47--2.93-
Stock-Based Compensation
586586----
Provision & Write-off of Bad Debts
68.0984.687.42-4.25-6.1729.55
Other Operating Activities
-1,101-60.97-176.661,7021,897-1,225
Change in Accounts Receivable
366.21-1,642-1,133-83.41-517.76-2,128
Change in Inventory
-473.3-802.12-97.7130.87-617.92-610.08
Change in Accounts Payable
-539.8--851.58-459.7517.831,293
Change in Other Net Operating Assets
-1,824-1,537-457.3-834.42-1,474207.98
Operating Cash Flow
2,9931,297377.993,340-1,610-67.7
Operating Cash Flow Growth
429.63%243.12%-88.69%---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-893.59-311.39-328.59-7,406-4,029-2,868
Sale of Property, Plant & Equipment
5.865.86--813.98-
Sale (Purchase) of Intangibles
-28.05-42.99-87.11-49.42-40.7-169.27
Investment in Securities
-11,948-11,9483,819-4,9658,9505,236
Other Investing Activities
-183.26-183.7-275.52-55.46-517.26-302.52
Investing Cash Flow
-13,047-12,4803,128-12,4765,1771,897

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
--664.11-615.54-859.19-671.84-490.16
Total Debt Repaid
-685.64-664.11-615.54-859.19-671.84-490.16
Net Debt Issued (Repaid)
-685.64-664.11-615.54-859.19-671.84-490.16
Issuance of Common Stock
-40,437----
Financing Cash Flow
-685.6439,773-615.54-859.19-671.84-490.16

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0.010.040.01-5.41-0.99-
Miscellaneous Cash Flow Adjustments
------0
Net Cash Flow
-10,73928,5902,891-10,0002,8941,339

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
2,099985.5649.4-4,065-5,639-2,935
Free Cash Flow Growth
523.41%1895.10%----
Free Cash Flow Margin
6.43%3.13%0.19%-14.90%-23.39%-15.87%
Free Cash Flow Per Share
89.0944.982.71-221.71-349.17-183.51
Levered Free Cash Flow
-327.22-1,055-3,001-7,596-933.3-3,846
Unlevered Free Cash Flow
-213.03-931.72-2,401-7,021126.36-2,919

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
170.98185.6210.9173.16116.04-
Cash Income Tax Paid
377.4858.45-2.53-3.1-54.9231.28
Change in Working Capital
-2,471-3,981-2,539-1,347-2,592-1,236